Optimizing the diabetic formulary: beyond aspirin and insulin (Q28193664)

Journal of the American College of Cardiology

Europe PubMed Central

title

Optimizing the diabetic formulary: beyond aspirin and insulin (English)

0 references

1 reference

Steven P Marso

1

0 references

language of work or name

English

0 references

publication date

21 August 2002

0 references

published in

0 references

volume

40

0 references

issue

4

0 references

page(s)

652-61

0 references

cites work

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Diabetes in America: epidemiology and scope of the problem

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

US public health and the 21st century: diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Diabetes and decline in heart disease mortality in US adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Hyperglycemia and cardiovascular disease in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Insulin and risk of cardiovascular disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Elevated C-reactive protein levels in overweight and obese adults

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

You are what you secrete

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

The hormone resistin links obesity to diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Clustering of cardiovascular risk factors in confirmed prehypertensive individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Cardiovascular risk factors and cognitive decline in middle-aged adults

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Compensatory enlargement of human atherosclerotic coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Diabetes as an atherogenic factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Evidence for abnormal platelet glycoprotein expression in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Potential mechanisms promoting restenosis in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021

Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902006-5

7 January 2021